Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Capex-to-Operating-Income : 21.22 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Biocytogen Pharmaceuticals (Beijing) Co's Capital Expenditure for the six months ended in Jun. 2024 was HK$-24.15 Mil. Its Operating Income for the six months ended in Jun. 2024 was HK$1.14 Mil.

Hence, Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income for the six months ended in Jun. 2024 was 21.22.

Biocytogen Pharmaceuticals (Beijing) Co Capex-to-Operating-Income Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Capex-to-Operating-Income Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	21.22

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income falls into.

Biocytogen Pharmaceuticals (Beijing) Co Capex-to-Operating-Income Calculation

Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-138.492)	/	-334.771
	=	N/A

Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-24.149)	/	1.138
	=	21.22

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Biocytogen Pharmaceuticals (Beijing) Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines